ePT--the Electronic Newsletter of Pharmaceutical Technology, Apr 7, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Apr 7, 2011
News
Pfizer’s Capsugel Fetches $2.375 Billion
By Rich Whitworth
After completing a strategic review of options for its Capsugel business, Pfizer announced on Apr. 04, 2011 that Kohlberg Kravis Roberts & Co L.P will acquire the pharmaceutical and dietary capsule company.
sanofi Completes Genzyme Acquisition
By Stephanie Sutton
sanofi-aventis has gained full control over Genzyme, bringing the much talked about acquisition deal between the two companies to a close.
J&J Reorganizes Consumer Group
By Erik Greb
Johnson & Johnson has instituted a new structure for its Consumer Group according to a Reuters report.
SOCMA Voices Concern over IST Provisions in Chemical-Site Security Measures
By Patricia Van Arnum
The Society of Chemical Manufacturers and Affiliates criticized the Secure Chemical Facilities Act, which would require chemical facilities to use inherently safer technology as part of chemical-site security measures.
Nigeria Looks to Simple Packaging Controls and International Cooperation to Curb Counterfeit Drugs
By Amy Ritter
Week of Apr. 7, 2011: Company and People Notes: ATMI Forms Distribution Pact with Finesse; AAIPharma Promotes Dean Shirazi; and More.
ATMI Forms Distribution Pact with Finesse; AAIPharma Promotes Dean Shirazi; and More.
Regulatory Roundup: New Web Search Feature on FDA.gov, Search for Product Recalls More Quickly
New Web Search Feature on FDA.gov, Search for Product Recalls More Quickly

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Click here